Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
Delayed Japan Exchange  -  02:00 2022-09-30 am EDT
1917.00 JPY   +0.63%
09/30European Medicines Agency Accepts Astellas Marketing Authorization Application for Fezolinetant
AQ
09/29European Medicines Agency Accepts Astellas Pharma Inc. Marketing Authorization Application for Fezolinetant
CI
09/29Lupin Gets US FDA Nod for Overactive Bladder Drug
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Verizon Business selected to transform Astellas Pharma's global network infrastructure

08/10/2022 | 09:33am EDT

JAPAN - Verizon Business has been selected to manage Astellas Pharma Inc's (Astellas) global network infrastructure.

The network transformation will enable Astellas to harness advanced technologies to help reduce drug development timelines, healthcare costs and drive new revenue opportunities for the Japanese pharmaceutical multinational.

Headquartered in Tokyo, Japan, Astellas is a global pharmaceutical company involved in the research, development, manufacture, and marketing of innovative new drugs under the vision of 'Stand on the forefront of healthcare change to turn innovative science into VALUE for patients'. The company employs 14,000 employees worldwide.

The company has identified digital transformation as a key driver of its business growth and began the search for a global partner to transform all aspects of its global technology infrastructure including building, designing and executing a next-generation secure network. In particular, Astellas was looking for a scalable and predictable platform that could seamlessly manage tens of thousands of devices and endpoints across Astellas' 70+ global locations across a virtualized multi-sourced environment.

Verizon's relationship with Astellas stretches back more than a decade. In 2016, Astellas successfully deployed Verizon's Secure Cloud Interconnect (SCI) solution to provide a high-bandwidth secure connection to its Amazon Web Services (AWS) and Microsoft Azure cloud services. Verizon's current remit includes the build and deployment of Astellas' global integrated network with a full suite of managed services, including Managed Wide Area Network, Local Area Network, Managed Security Services (MSS), Secure Gateway, Zero Trust Network Access and Unified Communications and Collaboration as a Service.

Shinya Suda, Senior Vice President, Information Systems, Astellas commented, 'From R&D to sales, we are seeing enormous amounts of data and intelligence flow through our business, across our 70 locations around the world. We want to ensure that we have a future-proof network in order to utilize cutting-edge technologies such as Artificial Intelligence, machine learning and robotics to make data-driven decisions to deliver better value for our patients. Our network transformation will underpin the next phase of our growth.'

'The network is transformative in its ability to enable innovation and growth and Astellas is changing the way they are using the tools at their disposal to completely revolutionize their business. This is truly a watershed moment for the pharmaceutical industry as companies grapple with the pressures of reducing time and costs for the development of drugs while improving patient care and value. We're proud to have been a part of Astellas' growth journey for more than a decade,' said Robert Le Busque, Regional Vice-President, Verizon Business Group, Asia Pacific.

Today's announcement builds on the company's network-as-a-service foundation and supports its private networks, mobile edge compute and business solutions vectors of growth.

Contact:

Nilesh Pritam

Tel: +65-62486599

Email: nilesh.pritam@intl.verizon.com

(C) 2022 Electronic News Publishing, source ENP Newswire

All news about ASTELLAS PHARMA INC.
09/30European Medicines Agency Accepts Astellas Marketing Authorization Application for Fezo..
AQ
09/29European Medicines Agency Accepts Astellas Pharma Inc. Marketing Authorization Applicat..
CI
09/29Lupin Gets US FDA Nod for Overactive Bladder Drug
MT
09/29ASTELLAS PHARMA INC. : Ex-dividend day for interim dividend
FA
09/27US Court Temporarily Bars US Drugmaker Hospira from Launching Generic Version of Astell..
MT
09/20Astellas and MBC BioLabs Announce Astellas Future Innovator Prize to Help Biotech Start..
AQ
09/12Seagen, Merck, Astellas Release Data From Trial of Padcev, Keytruda to Treat Bladder Ca..
MT
09/12Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV(R) (..
CI
09/04Astellas Pharma Inc. Announces Topline Results from Phase 3 Long-Term Safety Study of F..
CI
08/18Astellas Pharma Gets US FDA Nod on New Drug Application for Menopause
MT
More news
Financials
Sales 2023 1 454 B 10 051 M 10 051 M
Net income 2023 206 B 1 423 M 1 423 M
Net cash 2023 395 B 2 732 M 2 732 M
P/E ratio 2023 16,9x
Yield 2023 3,13%
Capitalization 3 503 B 24 207 M 24 207 M
EV / Sales 2023 2,14x
EV / Sales 2024 1,95x
Nbr of Employees 14 522
Free-Float 98,9%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 1 917,00 JPY
Average target price 2 596,15 JPY
Spread / Average Target 35,4%
EPS Revisions
Managers and Directors
Kenji Yasukawa Chairman, President & Chief Executive Officer
Minoru Kikuoka Chief Financial Officer
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Mamoru Sekiyama Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.1.84%24 207
JOHNSON & JOHNSON-4.51%432 579
ELI LILLY AND COMPANY19.47%313 567
ROCHE HOLDING AG-15.52%269 089
ABBVIE INC.5.41%252 343
PFIZER, INC.-25.89%247 841